Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors with Homologous Recombination-Deficiency Mutations
Research Background In recent years, Poly ADP-ribose Polymerase (PARP) inhibitors have shown significant efficacy as a key approach to treat hereditary BRCA1/2 mutation cancers. However, their effectiveness on tumors with other homologous recombination deficiency (HRD) gene mutations such as ATM, CDK12, and CHEK2 has been less satisfactory. Hence, ...